11. Myasthenia gravis Clinical trials / Disease details
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048785 | 2021-08-01 | 2021-07-16 | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with myasthenia gravis and thymic hyperplasia | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with myasthenia gravis and thymic hyperplasia | myasthenia gravis | Experimental group:Famciclovir antiviral treatment during perioperative period;Control group:No; | Tianjin Medical University affiliated General Hospital | NULL | Pending | Both | Experimental group:60;Control group:60; | N/A | China | ||
| 2 | ChiCTR2100049088 | 2021-08-01 | 2021-07-20 | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with thymoma complicated with myasthenia gravis | Evaluation of the effect of famciclovir anti-Epstein-Barr virus therapy on surgical treatment of patients with thymoma complicated with myasthenia gravis | thymoma | test group:Famciclovir antiviral treatment during perioperative period;Control group:Routine treatment of perioperative period; | Tianjin Medical University affiliated General Hospital | NULL | Pending | Both | test group:72;Control group:72; | N/A | China |